Although two SARS-CoV-2 variants are associated with higher transmission, patients with these variants show no evidence of higher viral loads in their upper respiratory tracts compared to the control group, a Johns Hopkins School of Medicine study found.
This study was performed at Dr. Heba Mostafa’s research laboratory, which has been performing large scale whole genome sequencing of SARS-CoV-2 for the State of Maryland and contributing data to the national publicly available surveillance figures.
The researchers investigated B.1.1.7 (Alpha), the variant first identified in the UK, and B.1.351 (Beta), first identified in South Africa, to evaluate if patients showed higher viral loads, and consequently increased shedding and transmissibility.
Variants were identified using whole genome sequencing. Researchers used a large cohort of samples to show that the Alpha variant constituted 75% of the circulating viruses by April 2021. The researchers compared 134 variant samples to 126 control samples and with access to the patients’ clinical information, were able to correlate the genomics data with the clinical disease and outcomes. All samples underwent additional testing to determine their viral load. The information was associated with the stage of the disease by looking at the days after the start of symptoms which added clarity in comparing viral shedding between groups.
“The reason why these variants show higher transmissibility is not yet clear,” said Adannaya Amadi, lead author on the study. “However, our findings did show that the patients infected with these variants are less likely to be asymptomatic compared to the control group. Although those infected with the variants were not at higher risk for death or intensive care admission, they were more likely to be hospitalized.”
The research is being presented this week at the World Microbe Forum online from June 20-24 live from Baltimore, Maryland.
